Back to top
more

2seventy bio, Inc. (TSVT)

(Delayed Data from NSDQ)

$4.60 USD

4.60
345,010

-0.12 (-2.54%)

Updated Oct 1, 2024 03:59 PM ET

After-Market: $4.61 +0.01 (0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Harmony Biosciences Holdings, Inc. (HRMY) Soars 8.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

2seventy bio, Inc. (TSVT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 60.78% and 236.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Lilly (LLY) Beats on Q4 Earnings, Lags on Sales, Raises '23 View

by Zacks Equity Research

Eli Lilly's (LLY) earnings surpass fourth-quarter estimates while sales slightly miss the mark. The company raises its EPS guidance for 2023.

J&J (JNJ) Down as Court Rejects Bankruptcy Claim in Talc Lawsuits

by Zacks Equity Research

A federal appeals court rejects J&J's (JNJ) efforts to shift over 38,000 lawsuits related to its talcum-based baby powder out of trial courts and into bankruptcy court.

How Much Upside is Left in 2seventy bio, Inc. (TSVT)? Wall Street Analysts Think 127.63%

by Zacks Equity Research

The consensus price target hints at a 127.6% upside potential for 2seventy bio, Inc. (TSVT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

bluebird (BLUE) Stock Dives on Public Offering of Common Stock

by Zacks Equity Research

bluebird (BLUE) to issue secondary shares, diluting its current shareholder base. The company plans to raise $120 million in gross proceeds from this issue.

bluebird (BLUE) to Boost Cash With Priority Review Voucher Sale

by Zacks Equity Research

bluebird (BLUE) is set to sell one of its two priority review vouchers. This will strengthen its financial position as its existing cash balance is expected to exhaust by second-quarter 2023.

bluebird (BLUE) Q3 Earnings Top, Revenues Miss Estimates

by Zacks Equity Research

While the commercial launch of Zynteglo is underway, bluebird's (BLUE) Q3 losses narrow but revenues miss estimates.

2seventy bio, Inc. (TSVT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of -1.15% and 25.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Does 2seventy bio, Inc. (TSVT) Have the Potential to Rally 97% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 96.9% in 2seventy bio, Inc. (TSVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

bluebird bio (BLUE) Focused on Pipeline Amid Marketed Drug Dearth

by Zacks Equity Research

bluebird bio's (BLUE) efforts to develop its gene-therapy pipeline are impressive. The FDA is reviewing BLUE's filing for beti-cel as a treatment for beta thalassemia and eli-cel for cerebral adrenoleukodystrophy.

Bristol Myers (BMY) Posts Data From Multiple Myeloma Study

by Zacks Equity Research

Bristol Myers (BMY) and partner, 2seventy bio, report top-line data from a late-stage study evaluating Abecma for multiple myeloma patients after two or more lines of prior therapy.

bluebird (BLUE) Q2 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

bluebird (BLUE) posts a narrower-than-expected loss in the second quarter. However, sales miss estimates.

bluebird (BLUE) Q1 Earnings and Sales Fall Short of Estimates

by Zacks Equity Research

bluebird's (BLUE) Q1 loss is worse than expected while sales lag estimates. It retains its dialogue with the FDA to resolve the clinical hold issue over its pipeline.

bluebird (BLUE) Posts Q4 Loss, Hit by Regulatory Pipeline Woes

by Zacks Equity Research

bluebird (BLUE) reports in-line fourth-quarter 2021 earnings but misses on revenues. The FDA placing clinical holds on BLUE's pipeline candidates does not augur well for the stock.

bluebird (BLUE) Filing for Thalassemia Therapy Gets Priority Review

by Zacks Equity Research

bluebird (BLUE) application seeking approval for beti-cel for thalassemia gets priority review in the United States.

bluebird (BLUE) Stock Down 19% on Q3 Earnings & Revenue Miss

by Zacks Equity Research

bluebird (BLUE) reports wider-than-expected loss for third-quarter 2021. It also misses revenue estimates. Shares decline 19% following the announcement.